We are live on ! Find out more
ANIX icon

Anixa Biosciences
ANIX

13 hedge funds and large institutions have $673K invested in Anixa Biosciences in 2016 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more capital inflows, than outflows

Capital inflows: $74.2K | Capital outflows: $51.1K

0.03% more ownership

Funds ownership: 1.4% → 1.43% (+0.03%)

0% more funds holding

Funds holding: 13 → 13 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
13
Holders Change
–
Holders Change %
0%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
4
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$70.4K
2
BlackRock Fund Advisors
BlackRock Fund Advisors
California
+$3K
3
Deutsche Bank
Deutsche Bank
Germany
+$750

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$19K
2
First Manhattan
First Manhattan
New York
-$13.3K
3
BA
Bard Associates
Illinois
-$8.88K
4
UBS Group
UBS Group
Switzerland
-$6.12K
5
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$3K

ANIX Hedge Fund Activity: Q4 2016 in Review

13 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Anixa Biosciences (ANIX) for Q4 2016, worth a combined $673K — up 41% from $477K a quarter earlier.

Fund positioning in ANIX was balanced in Q4 2016: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 4 trimmed.

The largest buyer was Vanguard Group, opening a new position worth an estimated $70.4K. The largest seller was Morgan Stanley, exiting entirely with an estimated $19K sold.

  • 13 institutional investors held Anixa Biosciences (ANIX) as of Q4 2016, unchanged from Q3 2016.
  • Funds reported $673K of Anixa Biosciences stock for Q4 2016, up 41% quarter-over-quarter.
  • 2 funds opened new Anixa Biosciences positions in Q4 2016 and 2 closed out, a net change of 0 holders.
  • The largest Anixa Biosciences buyer in Q4 2016 was Vanguard Group, an estimated $70.4K added.
  • The largest Anixa Biosciences seller in Q4 2016 was Morgan Stanley, an estimated $19K sold.

Based on aggregated 13F filings for Q4 2016.